drugset / Trial / NCT06600789
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
NaSequentialOpen-labelTreatment
Summary
This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.
Timeline
- Start
- 2024-08-16
- Primary completion
- 2026-04-22
- Completion
- 2026-05-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT7439 | Unknown | 0.5 mg | Oral |
| Subject | CT7439 | Unknown | 1 mg | Oral |
| Subject | CT7439 | Unknown | 3 mg | Oral |